There is minimal overlap in neurologic variations among individuals with severe psychiatric conditions such as schizophrenia spectrum disorders and bipolar disorder.
Pathways for Intellectual Disability in Children: Maternal Mental Illness vs Obstetric ComplicationsNovember 14, 2018
Investigators sought to determine the relationship between familial severe mental illness vs obstetric complications and the risk for developing intellectual disability
Investigators sought to determine whether cardioprotective medication after a myocardial infarction could reduce mortality rates in patients with schizophrenia.
Clozapine Monotherapy May Be Effective in Reducing the Severity of Antipsychotic-Induced Tardive DyskinesiaNovember 05, 2018
These results provide support for switching antipsychotics to clozapine in patients with moderate to severe tardive dyskinesia.
Safety, symptoms, and illness trajectory of outpatients with schizophrenia who received ongoing aripiprazole lauroxil were followed for 2 years.
Transition from a once-monthly formulation of a long-acting, injectable paliperidone palmitate to a once-every-3-month formulation treatment regimen in patients with schizophrenia demonstrated increased adherence to antipsychotic medication.
At 6 weeks of treatment, severely ill patients treated with adjunctive brexpiprazole had a greater reduction in PANSS total scores and CGI-S scores compared with those receiving placebo.
Existing 2-dimensional models are likely not sufficient to capture the complexity of negative symptoms in schizophrenia.
Interventions focused on emotion recognition may be effective in addressing sociocognitive deficits in patients with schizophrenia.
A team of UK-based investigators assessed functional and symptomatic outcomes in individuals with a first episode of psychotic disorder vs those associated with schizophrenia.
In an attempt to identify the risk associated with the comorbidity of type 2 diabetes and schizophrenia, a team of investigators from Taiwan assessed the impact of public health promotion efforts targeted at this population.
This research supports the monitoring of metabolic syndrome in patients with schizophrenia.
Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.
These data suggest that residential mobility may have a profound effect on the mental well-being of children and adolescents.
Timely categorization of patients as treatment-resistant or responsive may allow faster implementation of better targeted interventions.
In conclusion, these preliminary findings suggest that quetiapine is not a teratogen and could be used safely during pregnancy, but further research is needed to completely understand the risks involved.
Future studies should investigate how supplementation with vitamin D may improve symptoms and outcomes.
The study exhibited an overall conversion rate of 35% to a psychotic disorder.
Remission can be achieved for most cases of schizophrenia and schizophreniform disorder with amisulpride and clozapine.
The authors argue that identifying and treating sleep disorders during early stages may have a positive impact on outcomes in psychiatric patients.
Despite the associated risk for death and cognitive decline, "off-label" prescribing of antipsychotics in patients with dementia has increased.
The dose-response relationship observed between CBT and schizophrenia outcome may be salient to clinicians in titrating treatment strategies.
There was a significantly higher level of prolactin found in the first episode psychosis group than in the clinical high risk group, suggesting a condition of hyperprolactinemia.
Researchers found a suicide attempt rate of 12.0% in first-episode, drug-naive inpatients.
The findings support second generation long-acting injectable antipsychotic drug use as early treatment option to increase treatment adherence and to decrease the risk of relapse, hospitalization, and deteriorating social functions.
WSE treatment may be useful in addressing symptom exacerbation in schizophrenia and schizoaffective disorder.
Investigators examined factors that may improve employment in patients with schizophrenia.
Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.
These results may be helpful for clinicians when considering the effects of antipsychotic intervention on patient high-density lipoprotein cholesterol levels.
Inhalant and other substance use during adolescence are increasingly associated with many adverse health and psychosocial outcomes.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- FDA Approves Powerful New Opioid Despite Criticisms
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Updates in Borderline Personality Disorder: Your Questions Answered
- Violent Video Games Tied to Physical Aggression
- Shame Drives Suicidal Ideation Among Veterans With PTSD
- Long-term Healthy Diet Associated With Greater Hippocampal Volumes
- FDA to Ban Most Flavored Electronic Cigarettes
- Predictors of CBT Outcomes Identified in Youths With Anxiety Disorders
- Happy Childhood Memories Associated With Better Health
- FDA Launches MyStudies Mobile App in Effort to Increase Access to Real World Patient Data
- Heart Rate Variability Predicts Treatment Response in Anxious Depression